Production (Stage)
Xenon Pharmaceuticals Inc.
XENE
$29.75
-$0.74-2.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -33.32% | -28.48% | -21.90% | -21.58% | -27.92% |
| Total Depreciation and Amortization | 14.26% | 23.58% | -59.91% | 28.49% | 43.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 91.31% | 79.98% | 170.28% | 46.72% | 11.69% |
| Change in Net Operating Assets | 68.28% | -8.22% | -58.83% | -92.77% | -132.17% |
| Cash from Operations | -22.70% | -22.03% | -11.43% | -24.15% | -42.37% |
| Capital Expenditure | 18.59% | 45.26% | 67.49% | 53.99% | 26.37% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 225.83% | 261.75% | -238.36% | 31.07% | -1.02% |
| Cash from Investing | 222.12% | 250.84% | -249.28% | 31.93% | -0.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -96.24% | -96.57% | 997.83% | 50,044.96% | 30.65% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -96.24% | -96.57% | 997.83% | 50,044.96% | 30.65% |
| Foreign Exchange rate Adjustments | -2,638.00% | -544.68% | -128.50% | 58.32% | 98.16% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 644.09% | -106.49% | -205.31% | 123.63% | 77.43% |